Physician profile

Paul Updike

Internal Medicine · Buffalo, NY

NPI 1073544755

$385.52

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$30.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $71.19 2020-2021
Lilly USA, LLC $64.07 2020-2021
Novo Nordisk INC $52.10 2021
Takeda Pharmaceuticals U.S.A., INC. $42.51 2020
Orexo US, INC. $30.59 2023 Zubsolv
Indivior INC. $25.48 2019
Kowa Pharmaceuticals America, INC. $21.55 2022
Abbott Laboratories $20.73 2022
Almatica Pharma LLC $16.18 2021
Biohaven Pharmaceuticals, INC. $15.76 2021
Amarin Pharma, INC. $14.44 2021
Pfizer INC. $10.92 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul Updike

$385.52

in general payments reported 2019-2025

Years
2019-2023
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/229649/paul-updike

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.